Discontinued — last reported Q3 '21
License — Potential milestone payment receipts
Neurocrine Biosciences License — Potential milestone payment receipts remained flat by 0.0% to $55M in Q3 2021 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests a larger pipeline of partnered assets with high potential for future cash inflows, while a decrease may indicate the realization of milestones or the expiration of partnership terms.
Detailed definition
This metric represents the aggregate value of future contingent payments that the company is eligible to receive upon th...
Peer comparison
Common in biotech and pharmaceutical firms with out-licensing models; peers often disclose these as 'contingent consideration' or 'potential milestone payments' in footnotes.
nbix_segment_license_potential_milestone_payment_receiptsHistorical Data
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $55M | $55M |
| QoQ Change | — | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's license — potential milestone payment receipts?
- Neurocrine Biosciences (NBIX) reported license — potential milestone payment receipts of $55M in Q3 2021.
- What does license — potential milestone payment receipts mean?
- The total value of future payments the company could receive if its partners reach specific development or sales goals.